Literature DB >> 25185854

VEGF-A and PDGF-BB--angiogenic factors and the stage of diabetic foot syndrome advancement.

Ewelina Drela1, Arleta Kulwas, Wiesław Jundziłł, Barbara Góralczyk, Joanna Boinska, Wanda Drewniak, Grażyna Gadomska, Danuta Rość.   

Abstract

INTRODUCTION: In patients with diabetic foot syndrome (DFS), an inadequate angiogenic response is observed. The aim of this study was to evaluate the concentrations of VEGF-A, PDGF-BB, sVEGF-R2 and sVEGF-R1 in patients with diabetes-complicated diabetic foot syndrome and analyse them using selected clinical data.
MATERIAL AND METHODS: Forty seven diabetic patients, 25 women mean age 63 and 20 men mean age 60.5, with diabetic foot syndrome (DFS) were enrolled in the experimental group. To evaluate angiogenesis factors depending on Wagner grade, the subjects were divided into three subgroups: I - patients with 0 Wagner grade (n = 14); II - patients with 1,2,3 Wagner grades (n = 15); and III - patients with 4,5 Wagner grades (n = 18). The control group consisted of 20 healthy volunteers. The material for research was blood.
RESULTS: Significantly higher levels of VEGF-A and PDGF-BB in the DFS cases compared to controls were observed (VEGF-A p = 0.000001; PDGF-BB p = 0.000051). Analysis of angiogenic parameters according to the stage of diabetic foot syndrome advancement showed higher VEGF-A level (I: p = 0.000867; II: p = 0.001827; III: p = 0.000024) and PDGF-BB (respectively p = 0.004113, p = 0.004224, p = 0.002480) in all the subgroups. Decreased sVEGF-R2 concentrations were observed in the I (p = 0.054) subgroup and the III (p = 0.03524) subgroup. In this study, a strong positive correlation between VEGF-A and PDGF-BB was observed (R = 0.66; p = 0.000001).
CONCLUSIONS: Our study revealed that proangiogenic factor levels were increased in DFS. This is associated with lower limb ischaemia and hypoxic conditions. The stage of diabetic foot syndrome advancement influenced VEGF-A and PDGF-BB concentrations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25185854     DOI: 10.5603/EP.2014.0042

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  5 in total

1.  Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.

Authors:  Radosław Wieczór; Grażyna Gadomska; Barbara Ruszkowska-Ciastek; Katarzyna Stankowska; Jacek Budzyński; Jacek Fabisiak; Karol Suppan; Grzegorz Pulkowski; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2015-11       Impact factor: 3.066

2.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

3.  The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy.

Authors:  Ronald W Kartika; Idrus Alwi; Franciscus D Suyatna; Em Yunir; Sarwono Waspadji; Suzzana Immanuel; Todung Silalahi; Saleha Sungkar; Jusuf Rachmat; Mirta Hediyati Reksodiputro; Saptawati Bardosono
Journal:  Heliyon       Date:  2021-09-07

4.  Correlation between platelet-derived growth factor-B gene polymorphism and coronary heart disease.

Authors:  Yaru Lu; Hui Liu; Bo Dong; Jingyu Yang; Lu Kou; Qin Qin
Journal:  J Clin Lab Anal       Date:  2022-09-04       Impact factor: 3.124

5.  PDGF‑BB promotes the differentiation and proliferation of MC3T3‑E1 cells through the Src/JAK2 signaling pathway.

Authors:  Qi Liu; Yunfeng Zhou; Zubing Li
Journal:  Mol Med Rep       Date:  2018-08-03       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.